NASDAQ: XBIOXenetic Biosciences Inc Stock
$4.33+0.43 (+11.03%)
Updated Sep 14, 2026
XBIO Price
$4.33
Fair Value Price
N/A
Market Cap
$10.15M
52 Week Low
$1.90
52 Week High
$13.93
P/E
-3.73x
P/B
1.67x
P/S
2.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.26M
Earnings
-$2.48M
Gross Margin
100%
Operating Margin
-75.91%
Profit Margin
-75.9%
Debt to Equity
0.15
Operating Cash Flow
-$2M
Beta
0.85
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XBIO Overview
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XBIO's potential to beat the market
- XBIO doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
XBIO
RankedUnranked of 459
RankedUnranked of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $6.85 | A | |
| $41.54 | A |
Be the first to know about important XBIO news, forecast changes, insider trades & much more!
XBIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XBIO is good value based on its book value relative to its share price (1.67x), compared to the US Biotechnology industry average (5.35x)
P/B vs Industry Valuation
XBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XBIO due diligence checks available for Premium users.
Valuation
XBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.73x
Industry
8.25x
Market
43.6x
XBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.67x
Industry
5.35x
XBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XBIO's financial health
Profit margin
Revenue
$660.6k
Net Income
-$929.7k
Profit Margin
-140.7%
XBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
XBIO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.0M
Liabilities
$895.0k
Debt to equity
0.15
XBIO's short-term assets ($6.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XBIO's short-term assets ($6.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XBIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$875.5k
Investing
$0.0
Financing
$0.0
XBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XBIO vs Biotech Stocks
Xenetic Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.